Decreased Serum Brain-Derived Neurotrophic Factor Levels in Elderly Korean with Dementia by Lee, Jung Goo et al.
 
 
 
 
online © ML Comm   
Copyright ⓒ 2009 Official Journal of Korean Neuropsychiatric Association 299 
0ORIGINAL ARTICLE0 
Print  ISSN 1738-3684 / On-line  ISSN 1976-3026
OPEN ACCESS
DOI 10.4306/pi.2009.6.4.299 
 
Decreased Serum Brain-Derived Neurotrophic Factor 
Levels in Elderly Korean with Dementia 
 
 
 
ObjectiveaaThe primary purpose of this study was to investigate the differences in the se-
rum brain-derived neurotrophic factor (BDNF) level between elderly Korean people over 
65 years with and without dementia. 
Methodsaa171 individuals over 65 years were enrolled in this study. Screening for cogni-
tive impairments was carried out using the Mini-Mental Status Examination-Korean version 
(MMSE-KC). One hundred thirty-two subjects scored below 1.5 standard deviations (SD) 
of the mean MMSE-KC score, and these were evaluated using the Consortium to Esta-
blish a Registry for Alzheimer’s Disease, Korean version (CERAD-K) and the Geriatric 
Depression Scale (GDS). The Clinical Dementia Rating Scale (CDRS) and the Diagnostic 
and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) diagnostic criteria 
were used for further evaluation. Subjects with a CDRS score of 1 or higher were classified 
as having Alzheimer’s disease (AD), and subjects with a CDRS score of 0.5 were classi-
fied as having a mild cognitive impairment (MCI). Subjects with a CDRS score of 0 were 
classified as having aging-associated cognitive decline (AACD). Serum BDNF levels were 
analyzed using the enzyme-linked immunosorbent assay (ELISA) method. 
ResultsaaThe serum BDNF levels were significantly lower in the subjects with MCI and 
AD compared with the healthy controls (p<0.01). A significant correlation was found be-
tween the total MMSE-KC score and serum BDNF level (r=0.295; p<0.01). However, no 
significant correlation was observed between the severity of MMSE-KC and the total GDS 
score. A significant difference was found in the total score of GDS between the AACD group 
and subjects with AD (p<0.05). 
ConclusionaaThis study suggested that BDNF might be involved in the pathophysiology 
of cognitive decline in elderly people.   Psychiatry Invest  2009;6:299-305
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Introduction 
 
Dementia refers to a disease that causes the deterioration of general memory, speech, 
executive function, visuospatial function, and other cognitive functions. Patients with 
dementia also manifest behavioral disturbances, personality change, and emotional 
disturbances, and these symptoms often cause social, professional, or occupational im-
pairment.
1 Due to the rapid increase in the elderly population, the number of patients 
with dementia is also rising sharply, and the consequent problems affect not only the 
patients themselves but also their families, creating wider social problems.
2 It has been 
reported that Alzheimer’s disease (AD) accounts for approximately 50% of all de-
mentia.
3 The characteristics of AD are the formation of neuritic plaques due to the de-
position of beta-amyloid protein and the formation of neurofibrillary tangles in the
brain. Blasko and Grubeck-Loebenstein
4 reported that 10-20 years prior to the de-   
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velopment of AD, impairment of brain metabolism was 
already developing. It is thought that risk factors of AD 
include age, sex, education level, family history, head tr-
auma, a history of depression, and smoking.
5  
However, according to recent studies, neurotrophins 
such as brainderived neurotrophic factor (BDNF) might 
also be associated with the pathogenesis of AD.
6-9 Ha-
shimoto et al.
11 reported that the BDNF signaling path-
way and MetBDNF may affect memory and hippocam-
pal function in humans. 
BDNF polymorphism could be a risk factor for rapid 
disease progression in preclinical AD.
10,11 In postmortem 
brain analyses of patients with AD, the level of BDNF 
messenger RNA (mRNA) in the hippocampus and the 
cortex was decreased.
12,13 The reduction of the BDNF 
level in the hippocampus and the cortex is thought to in-
duce neurodegenerative changes in the brain.
14 Yasutake 
et al.
15 reported that serum BDNF concentrations were 
significantly lower in subjects with severe AD than in ei-
ther healthy controls or subjects with vascular dementia. 
Gunstad et al.
16 reported that higher serum BDNF levels 
were associated with better neuropsychological function 
in healthy older adults.   
Yu et al.
17 reported that reduced BDNF levels may play 
a role in the pathophysiology of amnestic mild cognitive 
impairemnt. In clinical studies, increased BDNF serum 
concentrations have been observed following treatment 
with lithium and donepezil.
18,19 
BDNF is a nerve growth factor that is expressed wi-
dely in the adult mammalian brain, and it has been sh-
own to play an important role in the development and 
survival of neurons. BDNF is a subject of interest in the 
study on the pathogenesis of neurodevelopmental or neu-
rodegenerative disorders.
20,21 
The incidence of depression in individuals with AD 
has been reported to be 23-51%.
22 A correlation is known 
to exist between cognitive function and depression.
22-24 
Depression, therefore, might be associated with a dete-
rioration of cognitive function.
25-27 So depression may 
have a negative effect on cognitive function and on the 
ability to perform the functions required for daily life in 
patients with AD.
2 Laske et al.
28 observed inverse cor-
relations between serum BDNF concentrations and de-
pressive symptoms. In this study, therefore, we investi-
gated whether serum BDNF concentrations differed be-
tween a normal group, an aging associated cognitive de-
cline (AACD) group, an mild cognitive impairment (MCI) 
group, and an AD group.   
We also evaluated the correlation between depression 
and serum BDNF concentration and the differences in 
serum BDNF concentration according to the severity of 
depression. 
Methods 
 
Subjects 
Six hundred twenty-eight subjects aged 65 years or 
older participated in this study. The subjects were patients 
who were able to participate in the project voluntarily 
during the research period, and a written consent was ob-
tained. The study protocol was approved by the Institu-
tional Review Board (IRB) of Busan Paik Hospital, Bu-
san. A dementia screening test was performed using the 
Korean version of the Mini-Mental State Examination 
(MMSE-KC), and for the final diagnosis of AD, the diag-
nostic standard of the Diagnostic and Statistical Manual 
of Mental Disorders, fourth edition (DSM-IV) and that 
of the National Institute of Neurologic and Communi-
cative Disorders and Stroke and Alzheimer’s Disease and 
Related Disorder Association (NINDS-ADRDA) were 
used.
29,30 A total of 371 subjects agreed to blood sampl-
ing to evaluate serum BDNF levels. A 5-cc sample of ve-
nous blood was collected from subjects between 11 : 00 
and 24 : 00 h each day. Subjects with or psychotic fea-
tures or history of depressive episodes according to DSM-
IV criteria were excluded from the study. In addition, 
subjects who had clinically significant physical abnor-
malities based on both physical and laboratory examin-
ation or who had a history of organic brain abnormality or 
psychotropic drug misuse were excluded from the study. 
 
Methods 
A screening test for dementia was performed on all sub-
jects using the MMSE-KC. One hundred subjects whose 
MMSE-KC scores were within 1.5 standard deviation (SD) 
of the mean were classified as “normal”, and no further 
tests for dementia were performed on these subjects. Th-
irty-nine subjects with MMSE-KC scores above 25 were 
selected as the normal control group. One hundred thirty-
two subjects had MMSE-KC scores more than 1.5 SD 
above the mean and underwent further, more comprehen-
sive examinations. These comprehensive tests were per-
formed using two testing steps. The first was the Korean 
version of the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD-K) neurocognitive battery, 
and the second was the full version of CERAD-K, which 
was administered by psychiatrists.
31 Subjects were clas-
sified according to their score on the Clinical Dementia 
Rating Scale (CDRS), which was a part of the second test. 
Forty-four subjects were classified as the 0-point group, 
41 subjects were classified as the 0.5-point group, and 47 
subjects formed the group higher than 1 point.   
Finally, members of the group with CDRS higher than 
1 point were evaluated by psychiatrists using the diag-
nostic standards of DSM-IV and NINDS-ADRDA, and  
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all members of the group were diagnosed with AD. Pre-
vious studies have reported that some individuals with a 
CDRS score of higher than 0.5 may be in the initial st-
ages of AD; however, in our study, they were all classi-
fied as having MCI.
32 
The diagnosis of MCI was performed using the diag-
nostic criteria proposed by Petersen et al.
33 These diag-
nostic criteria were as follows. 1) Subjects should have 
memory-impairment problems identified by informants, 
2) in comparison with their peers, subjects should have 
memory impairment, 3) relatively speaking, general cog-
nition should be conserved, 4) the ability to perform 
daily living activities should be conserved, and 5) they 
should not be diagnosed as having dementia. Among the 
subjects, those with MMSE-KC scores less than 1.5 SD 
from the mean were classified as “normal”, and there-
fore, comprehensive tests were not performed on them. 
However, these subjects may have had MCI. The sub-
jects with CDRS scores of 0 were not diagnosable as 
having MCI. However, the MMSE-KC scores adjusted 
for age and schooling were higher in these subjects than 
in others, by 1.5 SD; thus, they were considered to be-
long in the AACD group.   
The CDRS uses six detailed categories to evaluate 
cognitive function and all areas of social function in sub-
jects with dementia. The categories are memory, orien-
tation, determination and ability to solve problems, so-
cial activity, home life and hobbies, and hygiene and gro-
oming.
32 CDRS scores can be represented according to 
two different methods using scores in the above six ca-
tegories. The first method is to calculate the “Sum of 
Boxes (CDR-SB)” by adding the scores of all six cate-
gories. The second method is to determine the global CD-
RS score based on memory. According to this method, a 
CDR score of 0 indicates no dementia (none), and a CDR 
score of 0.5 indicates questionable dementia. A CDR 
score of 1 represents mild dementia, 2 indicates mode-
rate dementia, 3 indicates severe dementia, 4 suggests 
profound dementia, and a CDR score of 5 implies ter-
minal dementia. While evaluating CDRS, raters must be 
careful to evaluate only that functional deterioration ca-
used by cognitive impairment. Functional deterioration 
caused by physical conditions such as stroke or social 
and emotional problems should not be considered.
34 
For the evaluation of depression, the Geriatric Depres-
sion Scale (GDS) was used. This scale consists of 30 
questions and has previously been applied very usefully 
as a screening test for geriatric depression.
35 In this study, 
the Korean version of the Geriatric Depression Scale 
(GDS-K) was used.
36 The GDS-K was adopted during 
the second step of testing, and subjects with total GDS-K 
scores higher than 20 were considered to have depression.
36 
Measurement of serum brain-derived 
neurotrophic factor concentration 
Venous blood samples (5 mL) from the upper arm of 
each subject were collected in anticoagulant-free tubes 
between 08 : 00 h and 12 : 00 h. The samples were incu-
bated at room temperature for 1 h followed by 1 h at 
4℃ before the serum was isolated. Samples were then 
centrifuged at 2,000× g at 4℃  for 10 min. The superna-
tants were transferred to an Eppendorff tube, and the 
amount of BDNF was measured using enzyme-linked 
immunosorbent assay (ELISA) kits (Promega, Madison, 
WI, USA). Monoclonal anti-mouse-BDNF antibody was 
added to 96-well plates and they were incubated at 4℃ 
for 12 h. The next day, the plates were washed with a 
wash buffer (20 mM Tris-HCl pH 7.6, 150 mM NaCl, 
0.05% Tween 20), blocked for nonspecific binding, and 
incubated at room temperature for 1 h After washing, 
BDNF standards and samples were added to the wells, 
and plates were incubated for 2 h at room temperature. 
The anti-human BDNF antibody was then added and in-
cubated for 2 h at room temperature. After washing, the 
anti-IgY antibody conjugated to horseradish peroxidase 
was added and incubated for 1 h at room temperature. Any 
unbound conjugate was removed by washing. The solu-
tion was incubated with a chromogenic substrate, and the 
reaction was stopped using 1 N hydrochloric acid. BDNF 
concentration was measured at 450 nm using a microplate 
reader (SLT Spectra; SLT Instruments, Salzburg, Austria). 
 
Statistical analysis 
Chi-square tests and/or analysis of variance’s (ANO-
VA’s) were conducted to assess the demographic data. 
An ANOVA was used to analyze differences in serum 
BDNF concentration between the normal, AACD, MCI, 
and AD groups. We also used an ANOVA to assess differ-
ences in serum BDNF concentration according to the se-
verity of the depression. Pearson’s correlation test was 
used (p<0.05) to assess correlations among MMSE-KC 
scores, severity of depression, and serum BDNF concen-
tration. The Scheffe method was used for post-hoc analysis. 
 
Results 
 
Demographic data 
Educational level was significantly lower in the AD 
group than in any of the other groups (p<0.01). The mean 
MMSE-KC score of the AD group was significantly lo-
wer than that for any other group (p<0.01)(Table 1). 
 
Cognitive impairment and serum brain-derived 
neurotrophic factor concentration  
The average concentration of serum BDNF in the nor- 
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mal group was 27.9±6.9 ng/mL. In the AACD group, 
average concentration of serum BDNF was 24.2±7.4 
ng/mL; in the MCI group, it was 22.8±6.3 ng/mL; and 
in the AD group, it was 22.9±5.0 ng/mL. In the MCI 
and AD groups, average serum BDNF concentration was 
significantly lower than that in the normal group (p< 
0.01)(Figure 1).  
 
Cognitive impairment and depression 
The average GDS score of the AACD group was 19.5± 
7.2, the average score of the MCI group was 22.4±6.0, 
and the average score of the AD group was 23.3±4.9. 
The average GDS score of the AD group was signifi-
cantly higher than that for the AACD group (p<0.05) 
(Figure 2). The GDS score of the normal elderly group 
with MMSE-KC scores higher than 1.5 SD from the 
mean was not evaluated. 
 
Depression and serum brain-derived 
neurotrophic factor concentration  
In the 34 subjects with depression, the average con-
centration of serum BDNF was 23.3±6.1 ng/mL, whereas 
the average BDNF concentration among the 98 cases in 
the group without depression was 22.4±6.8 ng/mL; no 
significant statistical difference between the two groups 
was found (Figure 3).  
 
Korean version of the Mini-Mental State 
Examination score and serum brain-derived 
neurotrophic factor concentration 
A correlation was observed between MMSE-KC score and 
serum BDNF concentration (r=0.295; p<0.01)(Figure 4). 
TABLE 1. Demographic and clinical data of subjects 
MMSE-KC 1.5 SD below  MMSE-KC 0-1.5 SD 
 
CDRS 1≥  CDRS 0.5  CDRS 0  Raw score 25<  Raw score 25≥ 
No.  of  subject  47 41 44 61 39 
Sex (M/F)  14/33 17/24 20/24  8/53  16/23 
Age 75.1  (6.4) 74.1  (5.7) 73.0  (4.2) 75.4  (4.8) 72.8  (5.0) 
Education (years)**  03.1 (4.0)  05.8 (2.7)  06.5 (4.3)  06.6 (2.4)  06.7 (3.1) 
MMSE-KC** 13.7  (5.0) 17.9  (3.3) 19.1  (2.6) 19.8  (2.9) 27.4  (1.5) 
Mean (SD). **p<0.01 CDRS 0, 0.5 vs CDRS 1. MMSE-KC: Mini Mental State Examination of Korean version, CDRS: Clinical Dementia Rating 
Scale, SD: standard deviation 
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Korean version of the Mini-Mental State 
Examination score and depression   
In subjects with MMSE-KC scores of 1.5 SD below 
the mean, an analysis of the relationship between MMSE-
KC scores and GDS scores showed no significant cor-
relation. 
 
Discussion 
 
It has been reported previously that BDNF can cross 
the blood-brain barrier (BBB), and in animal studies, a 
positive correlation between the concentration of BDNF in 
the serum and in the cerebral cortex has been shown.
37-39 
Therefore, it could be inferred that a change in BDNF in 
the central nervous system may be associated with a cor-
responding change in serum BDNF.
12  
In this study, the correlation between cognitive impair-
ment and changes in serum BDNF concentration was 
evaluated. We also investigated the possibility of a cor-
relation between cognitive impairment and depression. 
We found that the more severe the cognitive impairment 
was, the greater the reduction of serum BDNF concen-
tration tended to be. This finding is similar to previous 
reports.
12 According to recent studies, neurotrophic fac-
tors such as BDNF are associated with the pathophysio-
logy of AD.
40 In postmortem analyses of the brains of 
patients with AD, BDNF concentrations in the temporal 
cortex and the hippocampus have been found to be de-
creased, as have BDNF concentrations in the frontal 
cortex.
41,42 In addition, it has been reported that the de-
position of beta-amyloid protein is involved in the syn-
thesis of BDNF and signal transduction, resulting in a 
blockage of, synaptic function and accelerated neuronal 
degeneration.
40 Such results support the hypothesis that 
a reduction of BDNF concentration is involved in the 
etiology of AD.   
Numerous studies have reported that after an ische-
mic brain injury, BDNF concentrations in the cranial cor-
tex and the number of neurons in the hippocampus were 
increased.
43-45 Such results strongly suggest that BDNF 
plays a neuroprotective role in ischemic brain injury. In 
a postmortem analysis of an AD brain, BDNF concen-
tration was also found to be increased. This study also 
hypothesized that the BDNF concentration was increas-
ed by a compensation mechanism.
46 Laske et al.
14 showed 
that in patients with mild Alzheimer-type dementia, se-
rum BDNF concentration was higher than in a healthy 
control group.
12 They assumed that BDNF concentration 
was elevated temporarily as a compensatory mechanism 
at the initiation of degenerative changes, and thus, serum 
BDNF concentration was higher in the mild AD group 
than in the normal group. In our study, most patients with 
AD were mild cases, and compared with the normal 
group, their serum BDNF concentration was lower. The 
result of our study contradicts the above result and thus 
does not support the compensation mechanism theory 
described above. However, our study did detect a positive 
correlation between MMSE-KC score and serum BDNF 
concentration, which supports previous findings.
12 There-
fore, the result of our study supports the hypothesis that 
a reduction of BDNF concentration is associated with a 
deterioration of cognitive function.
40 
We found that the average GDS score in the AD group 
was significantly higher than that in the AACD group. It 
is widely accepted that depression can be severe in in-
dividuals with AD.
22,47 It has also been reported that 
depression may be a risk factor for the development of 
AD.
48 However, in the present study, no significant dif-
ference in average GDS score was found between the 
MCI and AD groups.   
Generally, it could be predicted that depression would 
be more severe among individuals in the MCI group than 
among those in the AACD group, and it has been re-
ported that in subjects with MCI and accompanying de-
pressive symptoms, the prevalence of AD is increased.
49 
Depressive symptoms have a negative effect on cogni-
tive function and are therefore sometimes referred to as 
pseudodementia.
50-52 On the other hand, it has been also 
reported that neuronal degeneration progresses more ra-
pidly in the brains of subjects with AD.
53  
In the present study, no correlation was found between 
MMSE-KC and GDS scores. This finding contradicts pre-
vious studies showing that depressive symptoms are as-
sociated with a deterioration of cognitive function.
22-24,54 
A reason for this discrepancy could be that in this study, 
GDS was not evaluated for subjects with MMSE-KC 
scores of more than 1.5 SD from the mean, so correla-
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tions between the two groups could not be examined. In 
addition, the tests used in this study to assess cognitive 
function and depressive symptoms are used widely for 
screening tests, and thus in future research, correlations 
should be examined by applying more accurate and ob-
jective evaluation tools. Because of these limitations, any 
correlation between deterioration of cognitive function 
and depression could not be elucidated in our study. 
A comparison of serum BDNF concentration accord-
ing to severity of depressive symptoms revealed no sig-
nificant differences in this study. This contradicts the 
finding of a previous study, that in a group with depress-
ion, serum BDNF concentration was lower than in the 
healthy control group.
55 We found no correlation between 
depressive symptoms and serum BDNF concentration; 
nonetheless, the deterioration of cognitive function cor-
related with serum BDNF concentration. Thus, regard-
less of the presence or absence of depression in subjects 
with AD, BDNF concentration was decreased. This sup-
ports the hypothesis that a reduction of BDNF influences 
the deterioration of cognitive function. In this study, it 
has been suggested that a reduction of serum BDNF con-
centration may be viewed as a biomarker of the dete-
rioration of cognitive function.
12  
The limitations of this study are as follows. In the 
group with MMSE-KC scores lower than 1.5 SD below 
the mean, CDRS was not evaluated, and thus, some MCI 
patients were excluded from the study. Because GDS 
was not measured in this group, the correlation between 
depression and cognitive impairment could not be as-
sessed accurately. In addition, classification of cognitive 
impairment is generally applied to cases lower than 1.0 
SD from the mean, but in the present study, the AACD 
group was classified as those with a score lower than 1.5 
SD from the mean.
55 In addition, as mentioned above, 
some initial-stage AD patients are thought to have been 
included in the group with a CDRS score lower than 0.5; 
yet, in our study, all these subjects were classified as the 
MCI group.   
The results of our study support the hypothesis that 
BDNF concentration is involved in the pathophysiology 
of AD. Serum BDNF concentration among individuals 
varies greatly; nevertheless, a reduction of BDNF con-
centration in an individual may be applied as a bio-
marker of AD. In our study, a trend toward severe de-
pression was detected in subjects with AD but not in MCI 
patients.  
However, the correlation between the severity of de-
pressive symptoms and BDNF concentration could not 
be elucidated. Further research is required to reexamine 
this issue using supplementary research methods and more 
accurate evaluation tools. 
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